CORD-19:775b90287b44353bee979abb0970a4666022f86d / 489597-489703 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/775b90287b44353bee979abb0970a4666022f86d","sourcedb":"CORD-19","sourceid":"775b90287b44353bee979abb0970a4666022f86d","text":"She was then switched to monthly Canakinumab, and her disease continues to be in remission on Canakinumab.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"T7740","span":{"begin":0,"end":106},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T7740","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T273","span":{"begin":0,"end":106},"obj":"Sentence"}],"attributes":[{"subj":"T273","pred":"source","obj":"CORD-19_Custom_license_subset"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#ecb093","default":true},{"id":"CORD-19_Custom_license_subset","color":"#9693ec"}]}]}}